about
Cannabinoids for fibromyalgiaCannabinoids for fibromyalgiaFibromyalgia: evolving concepts over the past 2 decades.Re: Harth M, Neilson WR. Fibromyalgia and disability adjudication: no simple solutions to a complex problem. Pain Res Manag 2014;19(6):293-299The 2010 American college of rheumatology fibromyalgia survey diagnostic criteria and symptom severity scale is a valid and reliable tool in a French speaking fibromyalgia cohort.Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints.The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity.Management of chronic arthritis pain in the elderly.The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial.Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia.Adjudication of fibromyalgia syndrome: challenges in the medicolegal arena.The clinical concept of fibromyalgia as a changing paradigm in the past 20 years.Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials.Is there benefit in referring patients with fibromyalgia to a specialist clinic?Is a Responsive Default Mode Network Required for Successful Working Memory Task Performance?Management of chronic pain in the rheumatic diseases with insights for the clinician.Real-life assessment of the validity of patient global impression of change in fibromyalgia.Pain: understanding and challenges for the rheumatologist.Attitudes of Israeli Rheumatologists to the Use of Medical Cannabis as Therapy for Rheumatic Disorders.2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary.Fibromyalgia interacts with age to change the brainTreatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies.Evaluation of the clinimetric properties of the Early Inflammatory Arthritis--self-administered comorbidity questionnaire.Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines.Review of pharmacological therapies in fibromyalgia syndrome.New concepts in pain research and pain management of the rheumatic diseases.Opioid use, misuse, and abuse in patients labeled as fibromyalgia.Clinical implications for cannabinoid use in the rheumatic diseases: potential for help or harm?Canadian Pain Society and Canadian Rheumatology Association recommendations for rational care of persons with fibromyalgia: a summary report.The dilemma of medical marijuana use by rheumatology patients.Management of fibromyalgia in older adults.Multidisciplinary treatment for rheumatic pain.Treat-to-Target Strategy for Fibromyalgia: Opening the Dialogue.The impact of moving from a widespread to multi-site pain definition on other fibromyalgia symptoms.Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases.Management of fibromyalgia: practical guides from recent evidence-based guidelines.2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria.Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis.Opioid use in fibromyalgia is associated with negative health related measures in a prospective cohort study.Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia.
P50
Q24188267-7DDE259A-4D7A-4A09-8A13-AA85E7BBA10FQ26471052-172AE4D9-EE5C-4737-A8B8-81DB82964D23Q26999442-65397CD3-F82C-48C4-8B9C-B9995035ABC4Q28649434-27561E4D-0B28-4570-965F-98077DD55A3AQ31096632-81914D45-AFF2-4656-B00F-25185698B6B2Q33998887-A0D36EBC-9711-4B03-AA2D-F0FECBF5875FQ34114866-19191544-B883-47A6-A19E-C3235C77B6DDQ34119099-7040A0B3-A867-455E-8ED0-38DBD260425AQ34614801-877677E7-9BE5-428B-A14F-7D552D656F6DQ34626709-955D3B80-FC7C-453A-912E-74838AAEDC71Q34756165-FFAFB045-E781-48D3-9978-A684E7CA102EQ35495083-52726A9F-6E3A-41AB-8695-0128AECEB693Q35835342-C01312BB-EB01-4D77-B39D-D767E8CD19B4Q35966876-5682959E-0E16-4F66-96A9-A84367801BC5Q35968097-6E1AA16F-FD6F-4889-ACCD-48CB466863D8Q36056956-0EF04364-D32F-415F-958B-96507D49CDE5Q36215846-635B7C56-EC7C-4152-A54E-A9BBFCBAC1D0Q36331562-A0330B36-9000-4201-8415-18AA4366ACA6Q36821862-79CC60AB-2C40-424B-8678-7E1EA4D6B738Q36905958-92A51D10-A803-41AF-8590-EE3E3CEE1095Q37272666-3136487F-68A9-4446-A173-C147ECF492FEQ37375687-BBA9665C-C5E5-461E-AD14-00A6FD4CC616Q37385593-779BD8DB-92D3-480A-A3F5-AD5CC191AF5DQ37385744-B1723943-4647-4C8D-A131-B4CC2F3E4221Q37691161-468C1DB0-430B-4BCD-9A8C-33CFDA96F1DCQ37888224-047297D4-AA6A-4D48-8871-5E5BDB246A00Q37941138-6780E385-79FE-430A-B673-7345BFDBD449Q38011117-DFA2DB60-30BD-4BF1-8115-8ACDFC1F8D29Q38118752-7E1FCD3D-630E-499F-9F83-8E0CA9F88F4AQ38193035-4E4EA557-B82A-4ACB-B87E-9A544C484A4DQ38250183-71B814CC-B9D5-49F4-A2C1-7153677B2664Q38565363-67D274A7-7024-4D00-88EE-8290105D0988Q38889834-BD820BD1-98E2-4CA9-8C74-AB62F6B693DAQ38969463-1ECD210A-8060-4565-B435-9CD53B579667Q39004651-70D4C7BB-EA87-43EE-A714-61EFEED134B4Q39079528-C85A81F6-725F-4B2A-A22E-4FDCB29ED96CQ39132625-A85D1B9E-46A6-4B5D-9726-0144AF9C4749Q39189496-F281A3A0-D879-4B5C-9B1E-F47E191CB9CDQ39229180-14FC5513-0243-4973-8C44-21DEC4AC10D8Q39245884-3B852C02-FCEC-4CBF-AD68-0F021837DCDD
P50
name
Mary-Ann Fitzcharles
@ast
Mary-Ann Fitzcharles
@en
Mary-Ann Fitzcharles
@es
Mary-Ann Fitzcharles
@nl
type
label
Mary-Ann Fitzcharles
@ast
Mary-Ann Fitzcharles
@en
Mary-Ann Fitzcharles
@es
Mary-Ann Fitzcharles
@nl
prefLabel
Mary-Ann Fitzcharles
@ast
Mary-Ann Fitzcharles
@en
Mary-Ann Fitzcharles
@es
Mary-Ann Fitzcharles
@nl